ESMO 2018 | Improving the current chemotherapy standard: a role for DNA methyltransferase inhibitors

Simon Crabb

Currently, platinum-based chemotherapy is the standard of care for advanced patients with cancer. Here, Simon Crabb, MBBS, MRCP, PhD, of the University of Southampton, Southampton, UK, identifies a limitation of platinum-based chemotherapy, particularly for treating bladder cancer, and shares fascinating data to demonstrate the potential for a DNA methyltransferase inhibitor in improving the current chemotherapy approach. Results from the SPIRE trial (ISRCTN16332228) are shared and indicate safety and tolerability when guadecitabine is combined with cisplatin and gemcitabine. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Share this video